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 Introduction 
 Osteoporosis is one of the most common conditions 
associated with aging. It is defined as a skeletal disorder 
characterized by compromised bone strength predispos-
ing a person to an increased risk of fracture. Bone strength 
primarily reflects the integration of bone density and 
bone quality  [1] . The risk of fracture increases 1.5- to 3-
fold or more for each standard deviation (SD) decrease
in bone mineral density (BMD). A BMD value between
1 and 2.5 SD below the mean value for young adults is 
defined as low bone mass or osteopenia. A person with a 
BMD more than 2.5 SD below the adult mean value is 
considered to suffer from osteoporosis. This classifica-
tion has been established for lumbar spine bone mineral 
densities of postmenopausal women only. Nevertheless, 
the above-mentioned diagnostic categories are used for 
men as well as women.
 Many risk factors contribute to the pathogenesis of os-
teoporosis. Age-specific variations in bone density are 
mainly determined by genetic factors. Nevertheless, life-
style factors such as bone-loading physical activities, nu-
trition (calcium and vitamin D intake, alcohol consump-
tion), nicotine abuse, illnesses or the intake of medica-
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 Abstract 
 Osteoporosis, a classical age-related disease and known to 
be more common in women than in men, has been reported 
increasingly often in men during the past few years. Al-
though men at all ages after puberty have larger bones than 
women, resulting in greater bending strength, mortality af-
ter a hip fracture, one of the major complications of osteo-
porosis, is more common in men than in women. Sex hor-
mone deficiency is associated with unrestrained osteoclast 
activity and bone loss. Even though estrogen deficiency is 
more pronounced in women, it appears to be a major factor 
in the pathogenesis of osteoporosis in both genders. In con-
trast to osteoporosis in postmenopausal women, the treat-
ment of osteoporosis in men has been scarcely reported. 
Nevertheless, some drugs commonly used for the treatment 
of osteoporosis in women also appear to be effective in men. 
The aim of this study is to review primary osteoporosis in the 
elderly with particular emphasis on gender-related aspects. 
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tions with a negative impact on bone metabolism are 
additional risk factors for osteoporosis. 
 The aim of this review is to describe the epidemiology, 
pathophysiology, biomechanics, and therapy of osteopo-
rosis from the perspective of gender-related differences.
 Epidemiology and Clinical Relevance 
 The lifetime risk for a fragility fracture (distal forearm 
fracture, hip fracture, clinical vertebral fracture) in a 50-
year-old white US woman has been estimated to be ap-
proximately 40%, whereas the risk for a white US man is 
13%  [2] . In this study, the risk of a clinical vertebral frac-
ture was three times higher in women than in men. How-
ever, in the European Vertebral Osteoporosis Study  [3] 
and the Canadian Multicenter Osteoporosis Study  [4] , 
the prevalence of vertebral deformities was similar in 
men and women. The occurrence of fractures was found 
to increase with age in both sexes. Nevertheless, the curve 
was steeper in women than in men. 
 An analysis of risk factors in women and men with a 
clinical fracture showed a similar prevalence of bone-re-
lated risk factors in both genders, except for low body 
weight and a previous fracture after the age of 50, which 
are more common in women  [5] . Men experience frac-
tures at higher bone mineral density values than do
women.
 Osteoporotic fractures lead to pain and occasional 
disability. More importantly, they increase mortality. 
Mortality rates after hip fracture are 4-fold higher in men 
than in women  [6] . A vertebral fracture may be regarded 
as a risk factor for subsequent long-term morbidity, espe-
cially in women, and for mortality in both genders. The 
costs of treating fractures in women are higher than those 
for men.
 Pathophysiology 
 Bone Biology and Aging 
 Bone is a very active tissue that is remodeled through-
out life. The purpose of bone remodeling is to repair mi-
crodamage, adapt the skeleton to mechanical loading, 
and maintain calcium and phosphorus homeostasis. 
Bone remodeling is the consequence of a coupled action 
of bone-resorbing cells (osteoclasts) and bone-forming 
cells (osteoblasts). The bone remodeling cycle starts with 
the degradation of old bone by osteoclasts, which requires 
about 2–4 weeks. Osteoblasts then synthesize organic ex-
tracellular bone matrix (osteoid) and orchestrate its min-
eralization. Bone-forming processes take about 4–6 
months. After the formation and mineralization of new 
bone, the bone remodeling unit enters a resting phase.
 Osteoblasts, as adipocytes, fibroblasts, chondroblasts 
and myoblasts, differentiate from mesenchymal stem 
cells. After bone formation osteoblasts convert into inac-
tive lining cells, terminally differentiate into osteocytes, 
or undergo apoptosis. In contrast to osteoblasts, osteo-
clasts are derived from the hematopoietic lineage and can 
be generated from mononuclear precursors. A highly co-
ordinated communication between bone forming and 
bone-degrading cells is needed to maintain bone homeo-
stasis. Two cytokines – mainly produced by bone marrow 
stromal cells and osteoblasts – are essential and adequate 
for osteoclast generation: macrophage colony-stimulat-
ing factor (M-CSF), and receptor activator of nuclear
factor-kappa B ligand (RANKL). RANK, a receptor for 
RANKL, is expressed on osteoclast precursors. RANKL-
RANK interactions stimulate the differentiation and ac-
tivation of osteoclasts and inhibit osteoclast apoptosis. 
These processes are antagonized by osteoprotegerin, a 
natural decoy receptor of RANKL also mainly produced 
by stromal cells and osteoblasts [for review, see  7 ]. These 
interactions are already under clinical investigation with 
regard to their potential therapeutic application [re-
viewed in  8 ]. Whereas the RANKL/RANK/osteoprote-
gerin system mediating osteoblast-osteoclast coupling 
was identified as early as 10 years ago, signaling mole-
cules for osteoclast-osteoblast communication were only 
recently discovered. Osteoclasts express ephrinB2, whose 
receptor ephB4 is expressed by osteoblasts  [9] . The inter-
action between ephrinB2 and ephB4 appears to limit os-
teoclast activity and promote osteoblast differentiation.
 Generally speaking, osteoporosis results from any im-
balance between the activity of osteoblasts and that of 
osteoclasts, which leads to bone degradation. With re-
gard to aspects of bone formation, a number of experi-
mental and clinical studies have been published on the 
effect of age on the generation, differentiation and func-
tion of osteoblasts. Most – but not all – investigators reg-
istered a decrease in the osteoprogenitor pool of bone 
marrow with advancing age  [10] . Decreased osteoblasto-
genesis is also seen in the senescence-accelerated mouse 
P6 (SAMP6), a model of involutional osteoporosis associ-
ated with spontaneous fractures in old age  [11] . 
 An important and characteristic feature of the aging 
bone marrow is a shift from osteoblastogenesis to adipo-
genesis, leading to the accumulation of bone marrow fat. 
Runx2 is the first osteoblast-specific transcription factor 
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that was described. Runx2-deficient mice completely 
lack ossification because of the absence of osteoblast dif-
ferentiation  [12] . In contrast, peroxisome-proliferator-
activated receptor   2 (PPAR  2) inhibits osteoblast but 
promotes adipocyte proliferation. Several studies indi-
cate that the expression of runx2 in osteoblasts decreases 
with age ( fig. 1 ), while that of PPAR  2 increases  [13] . 
Thus, alterations in these transcription factors appear to 
explain – at least in part – the age-related shift from os-
teoblastogenesis to adipogenesis, and thus the transition 
from red to yellow bone marrow. 
 More insights into age-related process especially in 
bone can be appreciated from the pathogenesis of the 
Hutchinson-Gildford progeria syndrome. This is a dis-
ease caused by a mutation in the lamin A/C gene and is 
characterized by premature aging, including atheroscle-
rosis, alopecia and osteoporosis with spontaneous frac-
tures  [14] .
 Lamins are intermediate filaments that are important 
constituents of the inner nuclear membrane, and its ex-
pression has been found to decrease in osteoblasts of aged 
mice. Very recent data from our group indicate that 
knock-down of lamin A/C in human mesenchymal stem 
cells leads to a decrease of osteoblast proliferation, a re-
duction of runx2 mRNA expression and an increase in 
the RANKL/OPG ratio  [15] . Thus, these findings indicate 
a novel link between lamin A/C deficiency and age-re-
lated osteoblast insufficiency, a feature that is also seen in 
klotho-deficient mice (which exhibit many pathologies 
resembling human aging). 
 With regard to the effects of aging on osteoclast gen-
eration, contradictory data have been reported in the 
published literature. Perkins et al. [16] suggested that age-
related bone loss in mice is associated with an increase in 
the osteoclast progenitor pool, and that bone marrow 
cells from aged mice exhibit a greater ability to form os-
teoclasts. A greater capacity for osteoclast generation in 
mice was also registered by Cao et al.  [17] , as well as our 
group ( fig. 2 ), and was found to be related to increased 
mRNA expression of RANKL. In contrast, osteoclasto-
genesis is impaired in senescence-accelerated mice, pos-
sibly due to osteoblast insufficiency  [11] . Data from our 
laboratory  [18] show that, in aged male rats, serum 
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 Fig. 1. Gene expression of runx2 and alka-
line phosphatase (ALP) decrease in bone 
tissue and in osteoblasts with age.  a Bone 
marrow was flushed out of the femora of 
young (6-weeks) and old (18-months) 
BALBc mice. The bone tissue was crushed 
in liquid nitrogen. RNA was isolated and 
subjected to real-time PCR analysis for 
runx2 and ALP. Gene expression was nor-
malized to GAPDH.  b Bone marrow stro-
mal cells were isolated from the bone mar-
row of young (6 weeks) and old (18 months) 
mice and cultured for 21 days under osteo-
inductive conditions. RNA was isolated 
and subjected to real-time PCR analysis 
for runx2 and ALP. Gene expression was 
normalized to GAPDH.  * p  ! 0.01. 
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 Fig. 2. Number of osteoclasts increases in old mice. Osteoclasts 
were derived from murine (C57BL/6J) bone marrow stromal cells 
and were cultured for 7 days in the presence of 10 n M 1,25-dihy-
droxyvitamin D 3 . Cells were stained for tartrate-resistant acid 
phosphatase (TRAP). Multinucleated, TRAP-positive cells were 
counted as osteoclasts.  * * p  ! 0.01. 
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RANKL levels and ex vivo osteoclast generation are di-
minished despite demonstrable evidence of increased 
bone resorption. A decline in serum RANKL levels with 
age has also been registered in human studies  [19] and is 
in line with the age-related decline of RANKL expression 
in T cells ( fig. 3 ). Thus, data on effects of aging on RANKL 
expression, and osteoclast generation as well, are contra-
dictory. 
 Alternative approaches to investigate changes in the 
number and/or activity of cells involved in bone remodel-
ing are bone histomorphometry and the determination of 
biochemical markers of bone turnover. Most, but not all 
authors who used bone histomorphometry registered a 
decline in bone formation with age  [11, 20] . In men, serum 
levels of markers of bone formation (such as osteocalcin 
or bone-specific alkaline phosphatase) decline until the 
6th decade. Older men, on the other hand, were shown to 
demonstrate stable or increased as well as decreased bone 
formation markers  [21, 22] . A considerable number of 
studies have reported an increase in markers of bone for-
mation and bone resorption in postmenopausal women 
compared to premenopausal women  [21] , reflecting a high 
remodeling rate on histomorphometry. In older men, 
bone degradation as determined by biochemical markers 
appears to increase  [21, 22] . Thus, particularly with regard 
to bone formation, age-related changes in bone remodel-
ing appear to be gender spe cific.
 A Model of Involutional Osteoporosis 
 In 1983, Riggs and Melton  [23] proposed the existence 
of two distinct types of involutional osteoporosis: post-
menopausal (type 1) and senile (type 2) osteoporosis. 
Type 1 osteoporosis refers to the rapid phase of bone loss 
observed approximately 5–10 years after menopause, in-
volves mainly trabecular bone, and is manifested clini-
cally by fractures of the distal radius and vertebrae. While 
postmenopausal osteoporosis was recognized to be 
caused by estrogen deficiency, senile osteoporosis was at-
tributed to aging processes such as osteoblast dysfunc-
tion. Type 2 osteoporosis involves both trabecular and 
cortical bone. In addition to vertebral fractures, hip frac-
tures are also characteristic for this type of osteopo-
rosis.
 In 1998 the type1/type 2 model was reformulated as a 
‘unitary model of osteoporosis in postmenopausal wom-
en and aging men’  [23] . In the unitary model, estrogen 
deficiency was deemed to be the main cause of bone loss 
in early and also late postmenopausal women and elderly 
men. Estrogens have multiple effects on bone cells and 
mineral homeostasis. Estradiol inhibits the generation 
and activity of osteoclasts  [24] , effects mediated by an 
upregulation of osteoprotegerin. As mentioned above, es-
trogen withdrawal results in a high remodeling rate with 
excessive bone resorption and rapid bone loss. Eghbali-
Fatourechi et al.  [25] showed that upregulation of RANKL 
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 Fig. 3. Number of RANKL-expressing T 
lymphocytes and expression of RANKL 
on T lymphocytes decrease in old mice. 
Peripheral mononuclear cells were isolat-
ed from the spleen of young (6 weeks), 
adult (6 months) and aged C57BL/6J mice 
(18 months), stained with anti-RANKL 
(PE, eBioscience) and anti-CD4 (FITC, 
BD) and anti-CD8 (PerCP, BD), respec-
tively, and were subjected to flow cytomet-
ric analysis. Surface and intracellular ex-
pression of RANKL ( a ) and mean fluo-
rescence intensity ( b ) on CD4- and 
CD8-positive T cells.  * * p  ̂  0.01,  * * * p  ̂  
0.005. 
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in the bone marrow is an important mediator of high 
bone degradation in early postmenopausal women. 
 In addition to its effect on the RANKL/osteoproteger-
in system, estrogen deficiency leads to dysregulation of T 
cell function and antigen presentation. Pacifici et al.  [26] 
demonstrated that estrogen withdrawal results in in-
creased production of interleukin-7 (in part due to a de-
crease in transforming growth factor-  ), leading to T cell 
activation and greater release of interferon-  by T cells. 
Interferon-  upregulates the expression of major histo-
compatibility complex class II molecules, which results in 
augmented antigen presentation by bone marrow macro-
phages and dendritic cells. Consequently, T cells are fur-
ther activated and enhance the production of RANKL 
and tumor necrosis factor-  , which results in increased 
osteoclastogenesis  [26] . Notably, a progressive proinflam-
matory status has not only been associated with the post-
menopausal phase but also with aging in general; this 
phenomenon has been referred to as ‘inflamm-aging’ 
 [27] . Data from our laboratory suggest that some phe-
nomena of ‘inflamm-aging’ are gender specific: interfer-
on-  production by T cells increased with age in women, 
but not in men  [22] .
 The rapid phase of postmenopausal bone loss approx-
imately 5–10 years after menopause is followed by a slow-
er phase of continuous bone loss (‘senile bone loss’). No-
tably, extraskeletal consequences of estrogen deficiency 
(such as reduced intestinal calcium absorption) lead to a 
progressive elevation of PTH and further stimulate bone 
degradation  [23] . 
 Although testosterone deficiency in men is clearly as-
sociated with bone loss, estrogens appear to be even more 
important than androgens for male bones. This notion 
derives from several lines of evidence: the description of 
a mutated estrogen receptor gene in a young man with 
osteoporosis, observational studies demonstrating that 
estrogen levels correlate better than testosterone levels 
with bone mineral density  [28] , and intervention studies 
in elderly men showing a greater suppressive effect of es-
tradiol on bone resorption than testosterone  [28] . In men 
with idiopathic osteoporosis, estradiol levels are de-
creased, whereas sex-hormone-binding globulin (SHBG) 
levels and bone resorption markers are elevated  [29] . 
SHBG levels in men increase with aging. High SHBG lev-
els could significantly contribute to the development of 
osteoporosis by decreasing the bioavailability of estradiol 
(and testosterone), thus facilitating unrestrained osteo-
clast activity that exceeds bone formation. Recently, it has 
been suggested that the increase of serum SHBG is due to 
complex interactions between the reduction of pituitary 
growth hormone secretory capacity and decreased tes-
tosterone production by the testes  [28] . Despite the fact 
that estrogens are crucially important for bone health in 
women and men, it should be borne in mind that – in 
contrast to the abrupt cessation of ovarian function dur-
ing menopausal transition – there is a slight but steady 
decrease in estradiol and testosterone levels with aging
in men.
 Apart from estrogen deficiency, vitamin D deficiency 
is a major factor accounting for bone fragility in the el-
derly. It is well established that vitamin D levels decrease 
with aging  [22] ; in particular in residents of nursing 
homes, extremely low concentrations of vitamin D have 
been reported. If vitamin D levels are very low, the clini-
cal picture of osteomalacia may develop; the concomitant 
existence of osteoporosis and osteomalacia has been re-
ferred to as ‘osteoporomalacia’. Low levels of vitamin D 
in elderly subjects may result from a lack of sunlight ex-
posure, inadequate dietary intake, or medical conditions 
such as renal insufficiency. One of the major effects of the 
active metabolite of vitamin D, i.e. 1,25(OH) 2 vitamin D, 
is to increase the intestinal absorption of calcium and 
phosphate. Thus, in vitamin D deficiency intestinal cal-
cium absorption is decreased and may lead to hypocalce-
mia; as a consequence PTH levels increase. High PTH 
levels result in enhanced bone degradation which on the 
one hand counteracts hypocalcemia, but on the other 
hand in the long run leads to bone loss. 
 As will be discussed in more detail later, frequent falls 
in elderly subjects clearly increase the risk of fractures. 
Vitamin D receptors are not only expressed in bone but 
also in other tissues, including skeletal muscle. Vitamin 
D deficiency has been associated with muscle weakness 
and an increased frequency of falls; accordingly, vitamin 
D supplementation may reduce the risk of falling  [1] . 
 Biomechanics 
 Low bone mass is not the only factor contributing to 
the frequency of fractures in the aging population. As 
early as 20 years ago it was shown that, for a given bone 
mass, the risk of fractures increases with age, indicating 
the existence of other factors besides bone mass that pre-
dispose an individual to sustain a nontraumatic frac-
ture. 
 Factors most likely to influence the resistance to frac-
ture include the overall composition (i.e. proportion of 
mineral, collagen, water and matrix proteins), the physi-
cal and biochemical characteristics of these components 
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(i.e. nature of collagen, degree of mineralization), the 
morphology and architecture (i.e. bone size, geometry, 
trabecular microarchitecture), and the severity and na-
ture of pre-existing microdamage (i.e. crack length and 
location)  [30] . One example of trabecular bone loss and 
trabecular architectural disruption with aging is shown 
in  figure 4 . A balance between the mineral stiffness of 
bone and its flexibility is achieved by varying its mineral 
content  [31] . The greater the mineral content, the greater 
the material stiffness and the lesser its flexibility. The as-
sociation between areal BMD and vertebral fracture risk 
is explained by its correlation with more specific param-
eters of bone density, structure, and strength. Besides, 
bone structure, strength, and load-strength ratios con-
tribute to forearm fracture risk independently of areal 
BMD  [32] .
 As long as bone grows in length, periosteal apposition 
increases in diameter while concurrent endocortical re-
sorption excavates the marrow cavity. There is little dif-
ference between the genders with regard to the extent of 
periosteal apposition and net endocortical remodeling 
until puberty  [33] . Estrogen in girls inhibits periosteal 
bone formation, limiting the diameter of bone and simul-
taneously promoting net bone formation on the endocor-
tical surface. In boys, pubertal androgen production in-
creases periosteal apposition, bone diameter, and cortical 
thickness. Continued widening of the inner diameter 
shifts the cortex even farther from the neutral axis than 
the displacement that occurs in girls  [31] . Thus, young 
men have greater bending strength than do young wom-
en because bending strength increases with the distance 
from the neutral axis. However, cortical thickness is sim-
ilar in both sexes  [31] . The fact that men have larger bones 
at all ages compared to women  [31] may explain why 
stresses are higher in women compared to men when 
simulating a fall on the greater trochanter  [34] . A simu-
lated investigation of forearm behavior when falling 
showed that women had significantly less failure strength, 
bone mineral content, trabecular density and cortical 
area than did men  [35] . In premenopausal women, peri-
osteal apposition increases the width of the radius, partly 
offsetting endocortical resorption  [36] . During meno-
pause, increased periosteal apposition partially preserves 
bone strength  [36] . The postmenopausal period is char-
acterized by a further acceleration of endocortical re-
sorption, whereas periosteal apposition increasingly de-
clines [36]. Thus, the estimated cortical area and bending 
strength decrease in the postmenopausal period.
 Gender-related differences are found not only in pe-
ripheral bones. Men have greater vertebral strength at all 
ages, largely because of the greater cross-sectional area of 
vertebrae. The latter is estimated to be 25% less in women 
than in men  [37] . According to another study, periosteal 
bone formation increases vertebral body cross-sectional 
area to a 3-fold greater extent in men than in women, dis-
tributing loads over a larger cross-sectional area (CSA) so 
that the load imposed per unit CSA decreased twice as 
much in men than in women  [37] . The fact that women 
generally experience greater relative loads is in accor-
dance with other studies  [38] . The age-associated decline 
in vertebral strength is greater in women than men. In 
women, the ultimate load of the spine and the fracture 
risk score (i.e. quotient of estimated spinal load and esti-
mated ultimate strength) begin to decrease significantly 
after the fifth decade, whereas this occurs in men after 
the sixth decade  [39] . For bending and lifting, the risk of 
vertebral fractures, defined as the ratio of spinal load to 
vertebral strength, exceeded 1.0 in 30% of women and 
12% of men aged at least 50 years  [40] .
 Loading factors include the incidence and mechanics 
of falls, which occur more frequently in the elderly. One 
third of community-dwelling individuals older than 65 
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 Fig. 4. Bone mass is decreased in the vertebral column of aged mice. Representative   CT images of the fourth 
vertebral body of young (6 weeks), adult (6 months) and old (18 months) C57BL/6J mice. 
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years of age experience falls every year. Obviously, the 
more times an individual falls, the greater is the risk of 
fracture. Hip fractures are almost always due to a fall, but 
only 5% of falls result in fractures  [41] . The risk of hip 
fractures is greatest for a sideways fall that impacts on the 
greater trochanter. In such a case, the risk of hip fracture 
has been shown to rise up to 6-fold  [42] . Disturbance type 
and gait speed significantly affect the direction of a fall 
and location of the impact. Slipping or fainting while 
walking slowly is more likely to result in an impact on the 
hip, suggesting a greater risk of hip fracture  [43] . In the 
latter study, four types of disorders (faint, slip, step down 
and trip) were investigated at fast, normal and slow speed. 
A meta-analysis showed that a low body mass index is a 
risk factor for hip fracture even after adjustment for fem-
oral areal BMD  [44] . In women, a threefold increase in 
soft tissue thickness has been shown to reduce predicted 
peak force by 35%  [45] . In a recent investigation of human 
cadaveric specimens, it was found that each SD decrease 
in trochanteric soft tissue thickness was associated with 
a 1.8-fold increase in the risk of hip fracture  [46] . 
 Treatment 
 Osteoporosis-Specific Medication 
 Although there is still some discussion on the optimal 
dose, calcium and vitamin D supplementation is widely 
accepted as a fundamental basic measure for the preven-
tion and treatment of osteoporosis. However, large clini-
cal trials conducted over the past 15 to 20 years clear-
ly established that – in addition to calcium and vitamin 
D – patients with osteoporosis should receive specific 
pharmacologic treatment. In 2005, Riggs and Parfitt  [47] 
proposed a classification of drugs used to treat osteoporo-
sis, based on their action on bone remodeling. Anticata-
bolic drugs (such as bisphosphonates, or raloxifene – a 
selective estrogen receptor modulator) decrease bone re-
modeling and reduce fractures by preserving skeletal mi-
croarchitecture and moderately increasing bone mass. 
Anabolic drugs (such as teriparatide or PTH(1–84)), on 
the other hand, reduce fractures by enhancing remodel-
ing. In addition to substantially increasing bone mass, an-
abolic drugs appear to repair bone microarchitecture and 
improve bone geometry. Strontium ranelate, which is 
available for the treatment of osteoporosis in Europe, does 
not fit into the aforementioned classification because it 
inhibits bone resorption and stimulates bone formation. 
 There is a large body of scientific evidence derived 
from randomized controlled trials concerning the treat-
ment of osteoporosis in postmenopausal women; for a 
detailed discussion the reader is referred elsewhere  [1, 
48] . To summarize, a number of substances were shown 
to be effective against both vertebral and nonvertebral 
fractures: three different aminobisphosphonates (alen-
dronate, risedronate, zoledronic acid), teriparatide, stron-
tium ranelate and hormone replacement therapy (the lat-
termost is no longer recommended for the prevention or 
treatment of osteoporosis). Evidence of efficacy against 
vertebral fractures is available for ibandronate (an ami-
nobisphosphonate), raloxifene and PTH(1–84). 
 In contrast to postmenopausal women, osteoporosis 
in men is scarcely investigated. In 2000, the first large 
controlled trial on osteoporosis treatment in men showed 
that alendronate increased bone mineral density and pre-
vented vertebral fractures  [49] . In men receiving gluco-
corticoids, risedronate reduced the risk of vertebral frac-
tures  [50] . In a randomized open label study performed 
in men with primary or secondary osteoporosis, Ringe et 
al.  [51] found a significantly lower incidence of new ver-
tebral fractures in men treated with risedronate when 
compared to alphacalcidol. Although the above men-
tioned studies constitute a rationale for the treatment of 
osteoporosis in men, undertreatment of elderly men with 
osteoporosis is very common in clinical practice. Thus, 
further research needs to be conducted on gender-related 
aspects of the treatment of osteoporosis.
 Training 
 The public health burden of fractures cannot be re-
solved by drugs alone because drug trials have been large-
ly focused on women at the highest risk of fractures due 
to osteoporosis. However, a large number of individuals 
who suffer fractures have a bone mineral density even less 
than –2.5 SD below the normal value in young adults. 
Therefore, one goal is to achieve an acceptable bone min-
eral density in the general population. Prophylaxis should 
be started in childhood, with the aim of increasing peak 
bone mass. A 7-month exercise program of gradually in-
creasing intensity in pre- and early-pubertal girls showed 
greater changes in the cross-sectional area of femoral neck 
bone, cortical thickness, and section modulus in the in-
tervention group than in controls  [52] . According to ex-
perimental studies, the response to exercise is gender spe-
cific; the greatest effects are seen in male animals  [53] . 
 Vertebroplasty/Kyphoplasty 
 These methods of percutaneous cement injection pro-
vide minimally invasive options for the management of 
osteoporotic vertebral compression fractures. According 
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to a recent review, a mean restoration of 6.6° in the ky-
photic angle is achieved by both procedures  [54] . A large 
number of subjects experience some pain relief: 87% with 
vertebroplasty and 92% with kyphoplasty. With regard to 
complication rates, cement leaks occur in 41% and 9% of 
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spectively. Following either procedure, new fractures of 
adjacent vertebrae occur at rates higher than those regis-
tered in the general osteoporotic population, but approx-
imately equivalent to the general osteoporotic population 
that had experienced a previous vertebral fracture.
 Hip Protectors 
 As mentioned above, the risk of hip fracture is greatest 
for a sideways fall that impacts on the greater trochanter 
 [42] . An increase in the thickness of soft tissue has been 
shown to reduce the predicted peak force on the trochan-
ter  [45] . Thus, trochanteric padding systems designed to 
absorb part of the impact on the hip when falling may 
reduce the risk of hip fractures. However, the results of 
studies investigating hip protectors for prevention of hip 
fractures in the elderly are contradictory. Pooling data 
from eleven trials conducted in nursing or residential 
care settings, including cluster-randomized studies, dem-
onstrated a significant reduction in the frequency of hip 
fractures  [55] . However, pooling data from three individ-
ually randomized trials involving more than 5,000 com-
munity-dwelling persons showed no reduction in the fre-
quency of hip fractures  [55] . In line with the doubts ex-
pressed in this review concerning the effectiveness of hip 
protectors in the elderly, a more recent meta-analysis  [56] 
reported limited evidence of hip protectors preventing 
hip fractures in care homes. Many hip fractures occur in 
persons with a low risk for hip fractures or under circum-
stances that preclude the use of hip protectors. This may 
be the reason why the actual preventive effect of hip pro-
tectors is lower than its maximum potential preventive 
effect  [57] . Cost-effectiveness analyses are inconsistent in 
that they report positive as well as negative results. The 
primary acceptance of hip protectors as well as compli-
ance rates are low. 
 Compliance can be raised by providing information 
on the dangers of hip fractures as well as improving the 
design and mechanical properties of hip protectors  [58] . 
Soft-shell protectors are possibly more acceptable to users 
than the traditional hard-shell designs. However, in sim-
ulated sideways falls, soft-shell protectors were shown to 
achieve no more than a marginal reduction of the total 
impact force  [59] . Further clinical trials are needed to 
clarify this issue.
 Conclusion 
 Osteoporosis is an age-related disease with several 
gender-specific differences. Its prevalence is higher in 
women than in men. Due to their larger bones, men have 
greater bending strength than do women. However, once 
a hip fracture has occurred, mortality is higher in men. 
Differences in sex hormone production – especially the 
abrupt decline of estrogen in women – are responsible for 
inter-gender differences in the pathophysiology of osteo-
porosis. Finally, the treatment of osteoporosis also differs 
between genders; some therapy options can only be used 
in women.
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